Importantly, introducing NGS into clinical practice creates an opportunity to detect rare alterations such as the MET exon14 skipping mutation (3–4% of NSCLC patients), RET gene fusions (1–2% of NSCLC patients), NTRK gene fusions (approximately 1% of NSCLC patients) and exon 20 insertions of EGFR gene (1–2%) or HER2 gene mutations (2–4% of NSCLC patients). Here, MET is linked to non-small cell lung carcinoma.